Search

KLEPTOSE® HPB PARENTERAL GRADE - HYDROXYPROPYLBETADEX

KLEPTOSE®

®Registered Trademark(s) of Roquette Frères
  • Molecular encapsulation
  • Improve injectable API solubility and/or stability

Medium molecular substitution (MS) = 0.58 - 0.68

Applications

  • Injectable
  • Rx Injectable
  • Specialty APIs

Functional properties

  • APIs
  • Encapsulating agent
  • Excipients
  • Solubilizer
  • Stabilizer

Physical and chemical properties

  • CEP & DMF available

Documents

Product Specification Sheet

Region :

479,98 Ko

Safety Data Sheet

Region : Oceania, AU

EN 265,62 Ko

Region : Europe, BE

EN 511,81 Ko

Region : Americas, BR

EN 511,51 Ko

Region : Americas, BR

EN 528,87 Ko

Region : Americas, CA

EN 277,45 Ko

Region : Europe, CH

EN 512,21 Ko

Region : Asia, CN

EN 319,61 Ko

Region : Europe, DE

EN 514,94 Ko

Region : Europe, FI

EN 511,86 Ko

Region : Europe, FR

EN 512,25 Ko

Region : Europe, AT

DE 526,06 Ko

Region : Europe, BE

DE 525,88 Ko

Region : Europe, BE

FR 624,14 Ko

Region : Europe, BE

NL 519,92 Ko

Region : Americas, CA

FR 390,11 Ko

Region : Europe, CH

DE 524,03 Ko

Region : Europe, CH

FR 626,55 Ko

Region : Europe, CH

IT 613,61 Ko

Region : Asia, CN

ZH 633,49 Ko

Region : Europe, CZ

CS 642,17 Ko

Region : Europe, DE

DE 528,82 Ko

Region : Europe, DK

DA 521,41 Ko

Region : Europe, ES

ES 526,91 Ko

Region : Europe, FI

FI 528,28 Ko

Region : Europe, FR

FR 624,52 Ko

Get in touch with our Technical Experts

Please feel free to contact our technical experts for support during the development process.

Technical data

Synonyms HYDROXYPROPYLBETADEX
CAS number 128446-35-5
Physical form or apperance White or almost white amorphous powder. The statistical hydroxypropylation of beta-cyclodextrin creates a multitude of molecules, differing by the position of the hydroxypropyl groups. Consequently, the product is not able to crystallize and remains in the amorphous state.
Application KLEPTOSE® HPB parenteral hydroxypropyl β-cyclodextrin. It is a pyrogen-free solution that improves drug solubility and stability against light or oxidation by molecular encapsulation. It also reduces irritation at injection site.
Water sorption isotherm at 20°C
WATER_SORPTION
Chemical Structure
CHEMICAL_STRUCTURE
Glass Transition Temperature vs. Water Content
GLASS_TRANSITION
Viscosity in water at 2°C
VISCOSITY_IN_WATER
Surface Tension
SURFACE_TENSION
Osmolality
OSMOLALITY
Average molecular weight 1387 g/mol
Nominal Water content (LOD) 4.00
Maximal Water content (LOD) 10.00
Nominal molar substitution 0.62
Minimum Molar substitution range 0.58
Maximum Molar substitution range 0.68
Solubility Highly soluble in water. At high concentration, the wetting and dissolution time of the powder is delayed due to its low density and increased viscosity Soluble in ethanol. Freely soluble in propylen glycol.
Glass Transition Temperature of the Cryo-Concentrated Phase -10.30